Povorcitinib, a JAK1 inhibitor, offers rapid relief from chronic spontaneous urticaria (CSU) symptoms, as presented by Weilly Soong, MD, at the 2025 American College of Allergy, Asthma, & Immunology (ACAAI) Annual Scientific Meeting. The study revealed that povorcitinib significantly improved itch and hive symptoms within just 3 days, with a favorable safety profile. This is particularly crucial for patients who are resistant to antihistamines or biologics. The oral selective inhibitor targets mast cell disorders, blocking histamine release and itch pathways, and showed promising results in a phase 2 trial. Patients experienced meaningful improvements in hives and itch, with a hive score of 0 and an itch score of 0 reached by 50% and 53% of patients, respectively, at 12 weeks. The safety profile was generally well-tolerated, with no severe adverse events observed. However, the study's findings also highlight the pressing need for new effective therapies in CSU, as many patients are resistant to biological treatments due to external triggers or personal preferences. The future direction of povorcitinib research is uncertain, as the program is currently on hold due to company priorities. This study emphasizes the potential of JAK inhibitors in treating CSU and invites further exploration of this treatment avenue.
